PT - JOURNAL ARTICLE AU - Duckworth, Christopher AU - Guy, Matthew J AU - Kumaran, Anitha AU - O’Kane, Aisling Ann AU - Ayobi, Amid AU - Chapman, Adriane AU - Marshall, Paul AU - Boniface, Michael TI - Explainable machine learning for real-time hypoglycaemia and hyperglycaemia prediction and personalised control recommendations AID - 10.1101/2022.03.23.22272701 DP - 2022 Jan 01 TA - medRxiv PG - 2022.03.23.22272701 4099 - http://medrxiv.org/content/early/2022/03/23/2022.03.23.22272701.short 4100 - http://medrxiv.org/content/early/2022/03/23/2022.03.23.22272701.full AB - Background The occurrences of acute complications arising from hypoglycaemia and hyperglycaemia peak as young adults with type 1 diabetes (T1D) take control of their own care. Continuous glucose monitoring (CGM) devices provide real-time blood glucose readings enabling users to manage their control pro-actively. Machine learning algorithms can use CGM data to make ahead-of-time risk predictions and provide insight into an individual’s longer-term control.Methods We introduce explainable machine learning to make predictions of hypoglycaemia (<70mg/dL) and hyperglycaemia (>270mg/dL) 60 minutes ahead-of-time. We train our models using CGM data from 153 people living with T1D in the CITY survey totalling over 28000 days of usage, which we summarise into (short-term, medium-term, and long-term) blood glucose features along with demographic information. We use machine learning explanations (SHAP) to identify which features have been most important in predicting risk per user.Results Machine learning models (XGBoost) show excellent performance at predicting hypoglycaemia (AUROC: 0.998) and hyperglycaemia (AUROC: 0.989) in comparison to a baseline heuristic and logistic regression model.Conclusions Maximising model performance for blood glucose risk prediction and management is crucial to reduce the burden of alarm-fatigue on CGM users. Machine learning enables more precise and timely predictions in comparison to baseline models. SHAP helps identify what about a CGM user’s blood glucose control has led to predictions of risk which can be used to reduce their long-term risk of complications.Competing Interest StatementThe authors have declared no competing interest.Funding StatementThis study was funded by the UKRI Trustworthy Autonomous Systems Hub (Grant code: RITM0372366).Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:https://clinicaltrials.gov/ct2/show/NCT03263494I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesData is open source and can be found at https://clinicaltrials.gov/ct2/show/NCT03263494T1DType-1 DiabetesCGMContinuous Glucose MonitorAUROCArea Under the Receiver Operating CurveSHAPSHapley Additive exPlanations